Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($) |
Dec. 31, 2020 |
Dec. 31, 2019 |
---|---|---|
Income Tax Disclosure [Abstract] | ||
Net operating loss carryforward - Federal | $ 1,410,046 | $ 854,196 |
Net operating loss carryforward - State | 437,618 | 265,106 |
Stock option expense | 178,053 | 72,504 |
Depreciation | 12,958 | 8,753 |
Purchased in-process R&D | 2,405,997 | |
Federal orphan drug credits | 427,343 | 283,189 |
Start-up expenditures and amortization | 1,171,162 | 800,681 |
Total non-current deferred tax assets | 6,043,177 | 2,284,429 |
Valuation allowance for deferred tax assets | (4,139,829) | (1,165,126) |
Total deferred tax assets | 1,903,348 | 1,119,303 |
Intangible asset | (2,433,959) | (2,650,933) |
Total non-current deferred tax liabilities | (2,433,959) | (2,650,933) |
Total deferred tax asset (liability) | $ (530,611) | $ (1,531,630) |
X | ||||||||||
- Definition Deferred tax asset, acquired in-process research and development, tax affected. No definition available.
|
X | ||||||||||
- Definition Start-up expenditures. No definition available.
|
X | ||||||||||
- Definition Federal orphan drug credits. No definition available.
|
X | ||||||||||
- Definition Amount of deferred tax liability attributable to taxable temporary differences. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
X | ||||||||||
- Definition Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
X | ||||||||||
- Definition Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
X | ||||||||||
- Definition Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment. No definition available.
|
X | ||||||||||
- Definition Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
X | ||||||||||
- Definition Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
X | ||||||||||
- Definition Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
X | ||||||||||
- References No definition available.
|